Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19348655rdf:typepubmed:Citationlld:pubmed
pubmed-article:19348655lifeskim:mentionsumls-concept:C0033774lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C0011615lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C0038585lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C0439793lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C0771892lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C0449820lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C1442989lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C0332237lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C1522168lld:lifeskim
pubmed-article:19348655lifeskim:mentionsumls-concept:C0332293lld:lifeskim
pubmed-article:19348655pubmed:issue4lld:pubmed
pubmed-article:19348655pubmed:dateCreated2009-4-7lld:pubmed
pubmed-article:19348655pubmed:abstractTextAtopic dermatitis (AD) is a common chronic or chronically relapsing, severely pruritic, eczematous skin disease. Recently, substance P (SP) has been demonstrated to be one of the important neuropeptides for mediating itch-scratch and stress-scratch cycles. In this study, we examined the severity scores, itch scores and plasma SP levels in 19 patients with AD treated with standard topical therapy with or without an oral antihistamine, olopatadine hydrochloride, for 4 weeks. The standard therapy decreased SCORAD scores, itch behavioral rating scores and plasma SP levels at post-treatment in the mass, but the topical therapy with olopatadine was more effective than the topical therapy alone, suggesting a potential additive effect.lld:pubmed
pubmed-article:19348655pubmed:languageenglld:pubmed
pubmed-article:19348655pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19348655pubmed:citationSubsetIMlld:pubmed
pubmed-article:19348655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19348655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19348655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19348655pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19348655pubmed:statusMEDLINElld:pubmed
pubmed-article:19348655pubmed:monthAprlld:pubmed
pubmed-article:19348655pubmed:issn1346-8138lld:pubmed
pubmed-article:19348655pubmed:authorpubmed-author:FurueMasutaka...lld:pubmed
pubmed-article:19348655pubmed:authorpubmed-author:TakeuchiSatos...lld:pubmed
pubmed-article:19348655pubmed:authorpubmed-author:HosokawaChisa...lld:pubmed
pubmed-article:19348655pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19348655pubmed:volume36lld:pubmed
pubmed-article:19348655pubmed:ownerNLMlld:pubmed
pubmed-article:19348655pubmed:authorsCompleteYlld:pubmed
pubmed-article:19348655pubmed:pagination185-90lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:meshHeadingpubmed-meshheading:19348655...lld:pubmed
pubmed-article:19348655pubmed:year2009lld:pubmed
pubmed-article:19348655pubmed:articleTitleSeverity scores, itch scores and plasma substance P levels in atopic dermatitis treated with standard topical therapy with oral olopatadine hydrochloride.lld:pubmed
pubmed-article:19348655pubmed:affiliationDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.lld:pubmed
pubmed-article:19348655pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19348655pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:19348655pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19348655lld:pubmed